Alto Neuroscience (ANRO) Common Equity (2023 - 2026)

Alto Neuroscience has disclosed Common Equity across 4 years of filings, most recently posting $243.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $243.4 million, up 74.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $243.4 million (up 74.96% YoY), and the FY2025 annual result was $151.1 million, changed 0.21% from the prior year.
• Common Equity came in at $243.4 million for Q1 2026 at Alto Neuroscience, up from $151.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $243.4 million in Q1 2026 to a low of -$71.7 million in Q4 2023.
• The 4-year median for Common Equity is $139.1 million (2025), against an average of $94.4 million.
• Across the five-year window, Common Equity jumped 526.99% in 2024 and sank 32.41% in 2025, its largest moves.
• Alto Neuroscience's Common Equity stood at -$71.7 million in 2023, then soared by 311.32% to $151.5 million in 2024, then slipped by 0.21% to $151.1 million in 2025, then soared by 61.02% to $243.4 million in 2026.
• The last three Common Equity figures came in at $243.4 million (Q1 2026), $151.1 million (Q4 2025), and $111.6 million (Q3 2025), per Business Quant data.